InvestorsHub Logo
Followers 417
Posts 52354
Boards Moderated 13
Alias Born 12/16/2001

Re: None

Friday, 06/23/2017 1:01:40 PM

Friday, June 23, 2017 1:01:40 PM

Post# of 32013
MannKind (NASDAQ:MNKD) investors have a something to smile about today, but still need to keep the enthusiasm tempered to see if the spike in new scripts is something that can be maintained and whether or not the company is able to address the problems with poor refills.

For the week ending June 16, total Afrezza scripts came in above 380 with new scripts being the main cause of the sharp rise. Refills were essentially flat. As most investors are aware, MannKind shifted gears in management by promoting Mike Castagna as CEO. Castagna was the CMO over the past year and a half.


by Spencer Osborne
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent MNKD News